Loading organizations...
§ Private Profile · Billerica, MA, USA
AI-enabled remote cardiac monitoring solutions developer offering ECG monitoring and arrhythmia detection for healthcare institutions.
InfoBionic.Ai, based in Chelmsford, Massachusetts, United States, develops AI-enabled remote cardiac monitoring solutions, notably its MoMe ARC® platform for ECG monitoring and real-time data analysis. This system supports virtual cardiac telemetry, arrhythmia detection, and hospital-grade monitoring, improving patient outcomes and clinician workflows. Leveraging advanced biosensors and cloud-based AI, the platform provides FDA-approved 6-lead diagnostic capabilities. The company, which rebranded from InfoBionic in early 2024 to emphasize its AI focus, has completed 11 funding deals. These include a USD 57.765 million Series D round in September 2023, with investors such as Mayo Clinic and Excel Venture Management, to support expansion and the MoMe ARC® launch. InfoBionic.Ai was founded in 2011; founder names are not publicly available. Its business model centers on generates revenue through partnerships, subscriptions to the MoMe ARC® monitoring service, and service agreements for installation, maintenance, and support.
InfoBionic has raised $75.0M across 3 funding rounds.
InfoBionic has raised $75.0M in total across 3 funding rounds.
InfoBionic has raised $75.0M in total across 3 funding rounds.
InfoBionic's investors include Blue Cross and Blue Shield of Kansas, Eagle Proprietary Investments, Excel Venture Management, Safeguard Scientifics, Zaffre Investments, Al Wiegman, Broadview Ventures, Beta Fund, Boardwalk Investment, Boynton, Cherrystone Angels, HTC.
InfoBionic has raised $75.0M across 3 funding rounds. Most recently, it raised $50.0M Other Equity in September 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 11, 2018 | $50M Venture Round | — | Blue Cross And Blue Shield OF Kansas, Eagle Proprietary Investments, Excel Venture Management, Safeguard Scientifics, Zaffre Investments | Announced |
| Aug 5, 2015 | $8M Series B | Safeguard Scientifics | Excel Venture Management, Zaffre Investments | Announced |
| Apr 1, 2014 | $17M Series B | AL Wiegman | Broadview Ventures, Beta Fund, Boardwalk Investment, Boynton, Broadview Ventures, Cherrystone Angels, HTC, Keiretsu Forum, Launchpad Venture Group, Mass Medical Angels, TIE | Announced |
InfoBionic.Ai is a Massachusetts-based digital health company specializing in AI-enabled remote cardiac monitoring systems, recognized as the gold standard for virtual cardiac telemetry.[1][4][5] Its flagship product, the FDA-approved MoMe ARC® platform, provides hospital-grade, continuous ECG monitoring with AI-driven analysis, serving clinicians, hospitals, and patients by detecting arrhythmias and enabling proactive interventions to reduce hospitalizations and improve outcomes.[1][2][4] The platform features interchangeable pod-based sensors tailored to patient acuity, seamless IT integration, and near real-time data transmission, transforming ambulatory remote patient monitoring with high-fidelity data and clinical insights.[1][2][5]
Founded by a team of seasoned entrepreneurs with expertise in healthcare, IT, medical devices, mobile technology, remote monitoring, and cardiology, InfoBionic addressed the complexities of traditional cardiac arrhythmia detection processes.[5] CEO Stuart Long, with prior executive roles at CapsuleTech (acquired by Qualcomm Life) and Philips Healthcare, led the development of the transformative MoMe® platform, starting with innovations like MoMe® Kardia for beat-to-beat monitoring and instant alerts.[5] The company evolved from InfoBionic to InfoBionic.Ai in early 2024, emphasizing AI advancements in ECG analysis and remote telemetry, marked by partnerships like Anumana for earlier condition detection and the MoMe Gateway with NEXA and T-Mobile for scalable data transmission.[3][4][7]
InfoBionic.Ai rides the wave of AI-driven digital health and remote patient monitoring (RPM), capitalizing on post-pandemic demand for virtual cardiac care amid rising cardiovascular disease burdens.[4][5][7] Its timing aligns with healthcare's shift to proactive, data-intensive models, where AI enhances ECG workflows and enables earlier interventions, reducing hospital readmissions.[1][4] Market forces like regulatory pushes for RPM scalability, IT compliance (HIPAA, FDA), and cost efficiencies favor its no-infrastructure platform, influencing the ecosystem through partnerships with institutions, Anumana, and carriers like T-Mobile to standardize high-quality remote telemetry.[2][3][4]
InfoBionic.Ai is poised to expand its MoMe ARC® ecosystem with deeper AI integrations for predictive analytics and broader condition detection, potentially dominating virtual cardiac telemetry as RPM adoption accelerates.[1][4] Trends like AI validation from Mayo Clinic collaborations and "hospital-at-home" expansions will shape its growth, evolving its influence from monitoring leader to full-spectrum cardiac insight provider.[4] This positions it to further transform patient outcomes, tying back to its founding vision of turning cardiac data into actionable, life-improving clinical reality.[1][5]